18889881171
Kalkine 0
countryflagUS
L

AAPL 179.46 -1.1022% MSFT 361.16 0.9221% NVDA 99.8699 2.2838% GOOGL 147.7072 0.6523% GOOG 149.84 0.402% AMZN 175.8608 0.3428% META 519.62 0.6528% AVGO 161.55 4.8073% LLY 733.0192 1.2835% TSLA 232.8325 -0.1961% TSM 145.8853 -0.1948% V 317.355 1.6121% JPM 221.4275 3.2585% UNH 554.49 5.6775% NVO 62.055 -2.4906% WMT 84.375 0.6501% LVMUY 112.12 0.7186% XOM 103.0 0.0583% LVMHF 563.0 0.8961% MA 490.7 1.0669%
AAPL 179.46 -1.1022% MSFT 361.16 0.9221% NVDA 99.8699 2.2838% GOOGL 147.7072 0.6523% GOOG 149.84 0.402% AMZN 175.8608 0.3428% META 519.62 0.6528% AVGO 161.55 4.8073% LLY 733.0192 1.2835% TSLA 232.8325 -0.1961% TSM 145.8853 -0.1948% V 317.355 1.6121% JPM 221.4275 3.2585% UNH 554.49 5.6775% NVO 62.055 -2.4906% WMT 84.375 0.6501% LVMUY 112.12 0.7186% XOM 103.0 0.0583% LVMHF 563.0 0.8961% MA 490.7 1.0669%

Erasca Inc

Healthcare US ERAS

1.135USD
-0.09(7.35%)

Last update at 2025-04-08T16:43:00Z

Day Range

1.101.28
LowHigh

52 Week Range

1.513.38
LowHigh

Fundamentals

  • Previous Close 1.23
  • Market Cap717.51M
  • Volume1189700
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-139.51501M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.84

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

2019-12-312020-12-312021-12-312022-12-31-220M-200M-180M-160M-140M-120M-100M-80M-60M-40M-20M0M
Total Revenue
Net Income

Balancesheet

2019-12-312020-12-312021-12-312022-12-312023-12-310M50M100M150M200M250M300M350M400M450M500M
Total Assets
Total Liabilities

Change in Cash

2019-12-312020-12-312021-12-312022-12-31-50M0M50M100M150M200M250M

Total Operating Cash

2019-12-312020-12-312021-12-312022-12-31-110M-100M-90M-80M-70M-60M-50M-40M-30M-20M-10M

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -242.80500M -122.76400M -101.66000M -12.04000M
Minority interest - - - -
Net income -238.16000M -150.09000M -173.06900M -10.73700M
Selling general administrative 32.99M 22.62M 7.96M 3.68M
Selling and marketing expenses - - - -
Gross profit - - - -
Reconciled depreciation 2.64M 0.83M 0.54M 0.31M
Ebit -247.45000M -124.88300M 34.24M -13.29400M
Ebitda -43.45000M -68.19300M 34.78M -12.98400M
Depreciation and amortization 204.00M 56.69M 0.54M 0.31M
Non operating income net other -0.25700M 1.93M - -
Operating income -247.45000M -124.88300M 34.24M -13.29400M
Other operating expenses 145.45M 96.54M 37.51M 13.29M
Interest expense 201.36M 55.86M 0.34M 0.00000M
Tax provision - - - -
Interest income 4.90M 0.19M 0.34M 1.30M
Net interest income 4.90M 0.19M 0.34M 1.30M
Extraordinary items - - - -
Non recurring 102.00M 10.85M - -
Other items - - - -
Income tax expense -4.64500M 27.33M 71.41M -1.30300M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 145.45M 96.54M 37.51M 13.29M
Cost of revenue - - - -
Total other income expense net 4.64M 2.12M -135.89800M 1.25M
Discontinued operations - - - -
Net income from continuing ops -242.80500M -122.76400M -101.66000M -12.04000M
Net income applicable to common shares -242.80500M -122.76400M -101.66000M -12.04000M
Preferred stock and other adjustments - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 395.30M 514.91M 501.42M 124.83M 55.51M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 8.33M 8.88M 5.54M 1.29M 0.75M
Total liab 78.61M 103.06M 44.89M 238.81M 69.12M
Total stockholder equity 316.69M -480.97100M -238.16600M -113.98400M -13.60400M
Deferred long term liab - - - - -
Other current liab 20.19M 24.34M 2.88M 2.53M 0.64M
Common stock 0.01M 0.01M 0.01M 0.00300M 0.00300M
Capital stock 0.01M 0.01M 0.01M 0.00300M 0.00300M
Retained earnings -606.01300M -480.97100M -238.16600M -115.40200M -13.74200M
Other liab - 0.57M 0.16M - -
Good will - - - - -
Other assets - 5.18M 53.63M 0.76M 0.06M
Cash 93.08M 284.22M 360.49M 65.38M 29.58M
Cash and equivalents - - - - -
Total current liabilities 26.16M 48.69M 26.38M 13.68M 2.75M
Current deferred revenue - - 18.54M 9.40M -
Net debt -37.21600M -229.11900M -341.69600M -62.39000M -25.89400M
Short term debt 3.97M 1.30M 0.28M 0.88M 0.73M
Short long term debt - - - - -
Short long term debt total 55.86M 55.10M 18.79M 2.99M 3.69M
Other stockholder equity 922.61M 1.03M -501.26500M 1.41M 0.12M
Property plant equipment - 24.82M 15.95M 4.07M 4.33M
Total current assets 320.68M 444.50M 420.02M 119.99M 51.12M
Long term investments 9.64M 0.00000M 44.77M 0.00000M 0.00000M
Net tangible assets - 411.85M 456.53M -113.98400M -13.60400M
Short term investments 219.28M 151.40M 53.99M 53.33M 20.79M
Net receivables - - 0.10M - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 2.00M 23.05M 4.68M 0.88M 1.38M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.08M -1.04100M -0.16200M 0.00200M 0.01M
Additional paid in capital - - - - -
Common stock total equity - 0.01M 0.01M 0.00300M 0.00300M
Preferred stock total equity - - - - -
Retained earnings total equity - -480.97100M -238.16600M - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 4.38M 5.18M 3.32M 0.76M 0.06M
Deferred long term asset charges - - - - -
Non current assets total 74.62M 70.41M 81.40M 4.83M 4.39M
Capital lease obligations 55.86M 55.10M 18.79M 2.99M 3.69M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -52.53000M -45.70500M -32.51000M -20.29000M
Change to liabilities 0.68M 13.20M -0.38000M 1.17M
Total cashflows from investing activities -71.08100M -64.59000M -71.20200M -20.88700M
Net borrowings - - - -
Total cash from financing activities 98.08M 439.40M 139.99M 16.86M
Change to operating activities 15.11M 6.36M 3.67M 0.54M
Net income -242.80500M -122.76400M -101.66000M -12.04000M
Change in cash -76.27000M 295.21M 36.10M -14.40000M
Begin period cash flow 360.89M 65.69M 29.58M 43.98M
End period cash flow 284.62M 360.89M 65.69M 29.58M
Total cash from operating activities -103.26400M -79.60000M -32.68600M -10.37800M
Issuance of capital stock 95.25M 436.39M 136.97M 16.86M
Depreciation 2.64M 0.83M 0.54M 0.31M
Other cashflows from investing activities -4.00000M -7.68000M - -
Dividends paid - - - -
Change to inventory - - - -
Change to account receivables - - - -
Sale purchase of stock 0.82M 1.07M - -
Other cashflows from financing activities 2.00M 121.33M -71.20200M -20.88700M
Change to netincome 122.11M 19.18M 65.15M -0.36100M
Capital expenditures 16.55M 18.89M 38.69M 0.60M
Change receivables - - - -
Cash flows other operating 15.11M 9.85M - -
Exchange rate changes - - - -
Cash and cash equivalents changes -76.27000M 295.21M - -
Change in working capital 15.79M 7.71M 3.29M 1.71M
Stock based compensation 20.11M 8.33M 0.80M 0.12M
Other non cash items 101.01M 27.81M 71.75M -0.48300M
Free cash flow -119.81500M -98.48500M -71.37800M -10.97500M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
ERAS
Erasca Inc		 -0.09 7.35% 1.14 - - - 0.90 -0.2055
NVO
Novo Nordisk A/S		 -1.585 2.49% 62.05 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.59 0.93% 62.55 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.025 0.0053% 474.54 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -9.395 1.64% 563.38 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Erasca Inc

3115 Merryfield Row, San Diego, CA, United States, 92121

Key Executives

Name Title Year Born
Dr. Jonathan E. Lim M.D. Co-Founder, Chairman & CEO 1972
Mr. Ebun S. Garner J.D., Esq. Gen. Counsel & Corp. Sec. 1972
Dr. Wei Lin M.D. Chief Medical Officer 1970
Dr. Michael D. Varney Ph.D. Chairman of R&D, Scientific Advisory Board Member and Director 1958
Dr. David M. Chacko M.D. Chief Financial Officer 1984
Dr. Nik Chetwyn Ph.D. Sr. VP of Operations NA
Dr. Lisa Tesvich-Bonora Ph.D. Chief People Officer NA
Mr. Brian L. Baker CPA, M.S., MS, CPA Sr. VP of Fin. 1967
Ms. Chandra D. Lovejoy Sr. VP of Regulatory Affairs 1971
Dr. Robert Shoemaker Ph.D. Sr. VP of Research 1981

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.